Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 125 entries
View as:

Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01452646 Org: User:
Start: 01/31/12 End: 07/10/18 Due: 07/10/19

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Phase: N/A Priority: Normal
NCT ID: NCT01025505 Org: User:
Start: 06/30/12 End: 09/01/20 Due: 09/01/21

Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Phase: N/A Priority: Normal
NCT ID: NCT03465020 Org: User:
Start: 10/15/18 End: 07/31/23 Due: 07/31/24

An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04581187 Org: User:
Start: 12/02/20 End: 12/31/24 Due: 12/31/25

Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).

Phase: N/A Priority: Normal
NCT ID: NCT04378855 Org: User:
Start: 05/31/20 End: 05/31/25 Due: 05/31/26

Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03318770 Org: User:
Start: 05/10/19 End: 05/31/24 Due: 05/31/25

GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.

Phase: N/A Priority: Normal
NCT ID: NCT00439920 Org: User:
Start: 10/31/96 End: 12/31/18 Due: 12/31/19

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00896129 Org: User:
Start: 03/31/10 End: 12/31/10 Due: 12/31/11

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00462332 Org: User:
Start: 05/31/07 End: 06/30/11 Due: 06/30/12

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Phase: N/A Priority: Normal
NCT ID: NCT06090786 Org: User:
Start: 07/31/24 End: 07/31/27 Due: 07/31/28

Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults

Phase: N/A Priority: Normal
NCT ID: NCT01462253 Org: User:
Start: 10/31/12 End: 03/11/17 Due: 03/11/18

Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura

Phase: N/A Priority: Normal
NCT ID: NCT00657410 Org: User:
Start: 04/30/08 End: 02/29/16 Due: 02/28/17

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01154439 Org: User:
Start: 10/31/10 End: 09/15/15 Due: 09/15/16

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

Phase: N/A Priority: Normal
NCT ID: NCT06025682 Org: User:
Start: 04/04/24 End: 01/31/25 Due: 01/31/26

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02602314 Org: User:
Start: 11/11/16 End: 02/29/24 Due: 02/28/25

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT02398825 Org: User:
Start: 06/23/16 End: 12/27/22 Due: 12/27/23

AIDA 2000 Guidelines

Phase: N/A Priority: Normal
NCT ID: NCT01064570 Org: User:
Start: 05/31/00 End: - Due: -

Phase III Trial in Acute Promyelocytic Leukemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT00482833 Org: User:
Start: 08/31/07 End: 10/17/19 Due: 10/17/20

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Phase: N/A Priority: Normal
NCT ID: NCT04174612 Org: User:
Start: 04/24/20 End: 08/01/25 Due: 08/01/26

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00769327 Org: User:
Start: 02/09/09 End: 10/10/14 Due: 10/10/15

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00458848 Org: User:
Start: 10/31/04 End: 03/31/14 Due: 03/31/15

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01156883 Org: User:
Start: 04/30/10 End: 10/31/17 Due: 10/31/18

Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT01752062 Org: User:
Start: 05/02/13 End: 12/31/22 Due: 12/31/23

Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches

Phase: N/A Priority: Normal
NCT ID: NCT04460963 Org: User:
Start: 06/09/21 End: 06/30/24 Due: 06/30/25

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03751917 Org: User:
Start: 04/14/20 End: 12/31/24 Due: 12/31/25